Las Vegas, Nevada 2021-09-27 21:38:24 –
(NEXSTAR) – Pfizer CEO says he is about to submit the results of a COVID-19 vaccine trial in children aged 5-11 to become the first regulatory-approved vaccine maker. increase.
“I think this data will be submitted soon. It’s a matter of days, not weeks,” Albert Bourla told ABC “this week” on Sunday.
Earlier this month, Dr. Peter Marks, FDA’s head of vaccines, said Said He “very, very hoped” that children in that age group could be vaccinated against COVID-19 by the end of the year or earlier.
Marks said he hopes the FDA will be able to analyze Pfizer’s findings “within a few weeks.”
Many parents, teachers and civil servants are worried about increased access to the vaccine as the Delta variant continues to tear the unvamped population, including school-age children.Currently, almost all COVID-19s are dead in the United States Someone who is not vaccinated..
U.S. health officials have more than 40 million coronavirus vaccines available, sufficient for both older Americans eligible for booster shots and infants whose initial vaccine is not expected to be approved too much. He said he was confident that there was. In the distant future.
Soaring Demand — Last Week Federal Recommendations on Booster Shots — The first significant increase in a few months. Over 70 million Americans remain unvaccinated, despite lottery prizes, free food and gifts, and the temptation of plea from exhausted health care workers. The average number of deaths per day exceeded 1,900 In the last few weeks.
Federal and state health officials said that current supply and steady production of higher doses could easily accommodate boosters or those seeking the first vaccination, and the COVID-19 vaccine, which is frustratingly slow nationwide earlier this year. He said that it is possible to avoid repeating the expansion of.
The Associated Press contributed to this report.